A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Phase of Trial: Phase II
Latest Information Update: 20 Mar 2019
Price : $35 *
At a glance
- Drugs Vimirogant (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Vitae Pharmaceuticals
- 17 May 2018 Status changed from active, no longer recruiting to discontinued.
- 22 Mar 2018 Status changed from not yet recruiting to active, no longer recruiting.